Your capital budget was approved four months ago. The nursing informatics team validated the Zebra TC52ax-HC units during the pilot. Everyone agrees these are the devices the clinical floors need.
Then the carrier rep tells you they don’t stock them. The GPO contract covers med-surg supplies but not enterprise mobility. The OEM’s Canadian allocation is spoken for until next quarter—and your fiscal year ends in eight weeks.
This isn’t an edge case. It’s the default experience for Canadian health systems trying to procure purpose-built clinical devices through channels designed for consumer hardware.
The challenge runs deeper than availability. Nearly half of Canadian healthcare IT decision makers say they cannot deploy and manage new devices—the second-highest rate globally, trailing only the UK. For procurement managers and IT directors, this means the sourcing decision can’t be separated from the deployment question. A partner who can find the device but can’t stage, image, and deploy it doesn’t actually solve your problem.
This post walks through the evaluation criteria that separate a genuine clinical device procurement partner from a general reseller—specifically for Canadian healthcare buyers navigating PHIPA, provincial procurement directives, and a device market that doesn’t work the way consumer hardware does.
Before evaluating partners, though, it helps to understand why clinical device procurement is structurally different from every other hardware category hospitals buy.
Why clinical device procurement doesn’t work like standard hospital IT purchasing
A procurement team runs a standard RFP for 400 mobile computers. Three carriers respond with consumer-grade smartphones. One general IT VAR offers the right SKU but can’t confirm their Medical Device Establishment Licence status or PHIPA-compliant staging capabilities. The OEM direct team says they only sell through authorised channel partners in Canada.
The RFP process took 12 weeks. The OEM allocation window was eight.
This scenario plays out in Canadian hospitals more often than most procurement professionals expect—because clinical device sourcing operates under constraints that don’t apply to laptops, network switches, or standard IT peripherals.
Canadian hospitals routinely experience meaningfully longer lead times for healthcare-grade rugged mobile computers than equivalent US institutions. The math is straightforward: Canada’s market represents roughly one-tenth of the US volume, which translates directly into smaller OEM allocations and longer wait times for specialised SKUs.
The supplier pool narrows further when you factor in domestic sourcing requirements. At large Canadian hospitals, 93% of Tier 1 procurement spend goes to Canadian-based vendors—a pattern that reflects both policy preferences and practical supply chain resilience, but one that limits options for specialised categories like clinical mobility.
Here’s what actually happens when a hospital specifies a clinical-grade device: products like the Zebra TC52ax-HC or Honeywell CT45-HC are channel-only. They don’t appear in carrier retail catalogues or on general B2B reseller websites with meaningful Canadian inventory. They move through OEM-authorised partner programs—Zebra PartnerConnect, Honeywell Performance Partners—and the number of Canadian partners holding both the OEM authorisation and a Health Canada Medical Device Establishment Licence is small.
Most procurement teams discover this after the RFP is already in market.
The structural reality shapes everything that follows: which partners can actually deliver, which timelines are realistic, and which evaluation criteria matter most.
Clinical-grade hardware requirements that should drive your evaluation
The phrase “healthcare-grade” appears on a lot of product pages. In procurement terms, it means a specific set of capabilities: antimicrobial housings rated for 30+ chemical disinfectants and UV-C sterilisation, sealed enclosures that survive repeated exposure to hospital cleaning protocols, IP-rated ingress protection, barcode scanning optics that achieve greater than 99% first-pass read rates on patient wristbands, and battery architecture that lasts a full 12-hour nursing shift without a swap.
These aren’t nice-to-haves. They’re the baseline for devices that survive clinical environments without becoming infection vectors or workflow bottlenecks.
Device families that meet clinical standards
Three OEM ecosystems dominate Canadian clinical procurement. Zebra Technologies offers the TC52x-HC and TC52ax-HC handhelds, the MC93ax-HC for warehouse pharmacy, the CC6000 patient self-service kiosk, and the ZD510-HC wristband printer—all designed for clinical environments. Honeywell’s CT45 and CT45 XP healthcare variants and the EDA52-HC serve similar use cases with different ergonomic profiles. Samsung’s Galaxy XCover series with Knox Configure provides a consumer-adjacent option for less demanding clinical workflows.
Apple iPad and iPhone with supervised MDM profiles serve a different clinical use case—physician rounding, administrative tasks—not bedside scanning where antimicrobial housing and barcode optics matter most.
The device selection itself is usually the easy part. Clinical informatics teams know what they need. The hard part is finding a Canadian supplier who can actually deliver it.
What your vendor’s OEM authorisation actually tells you
OEM partner programs are tiered. Zebra PartnerConnect has distinct levels—Registered, Premier, Summit—each with different allocation priority, pricing access, and technical support escalation paths. Honeywell Performance Partners and Samsung’s B2B program follow similar structures.
Partner tier matters because it determines whether a vendor can actually deliver the device you specified within your timeline. A vendor at a lower partner tier may quote the right SKU but lack the allocation to fulfil your order when competing against higher-tier partners for the same limited Canadian inventory.
The infrastructure challenge compounds the device challenge. Ninety-nine percent of Canadian healthcare organisations still rely on some legacy infrastructure, and 71% use outdated systems to operate telehealth and IoT devices. New clinical devices must integrate with what the hospital has today—not just the target-state architecture in the digital health roadmap.
When a hospital specifies a device model in their capital plan 12 months before deployment, the OEM may announce end-of-sale on that SKU inside the procurement window. A sourcing partner with deep OEM relationships can identify the successor SKU, confirm clinical equivalence, and update the procurement documentation—before the capital dollars are stranded on a device that no longer ships.
That proactive lifecycle awareness is the difference between a sourcing partner and a reseller who happens to have the right product listed.
PHIPA-compliant supply chain—the criterion most evaluations underweight
Under PHIPA, any third-party vendor that touches a device containing or destined to contain personal health information is legally classified as an “agent” of the health information custodian. The hospital remains accountable for what that agent does.
This means the vendor staging your clinical devices in their facility, imaging them with your MDM profile, and shipping them to your nursing units is operating inside your PHIPA compliance perimeter—whether you’ve formalised that relationship or not.
The compliance stakes have never been higher. As of January 1, 2024, Ontario’s Information and Privacy Commissioner can impose administrative monetary penalties of up to $500,000 per organisation for PHIPA contraventions. The first such penalty was issued in August 2025.
For healthcare procurement leaders, this transforms vendor selection from a cost-optimisation exercise into a risk-management decision.
What a PHIPA agent agreement should cover
A proper agent agreement specifies security obligations, subcontracting limits, breach-notification timelines, audit rights, and logging and monitoring requirements. It’s not a checkbox document—it’s the legal instrument that determines your exposure if something goes wrong at the vendor’s facility.
The TransForm ransomware attack in October 2023 offers a cautionary example. Five southwestern Ontario hospitals went offline. Systems weren’t fully restored until February 2024. The incident cost over $7.5 million and compromised more than 516,000 records. A subsequent Ontario Superior Court ruling in the Hospital for Sick Children v. Ontario IPC case established that even an email account compromise lasting as little as one hour constitutes unauthorised disclosure under PHIPA.
Apply that standard to a device staging facility. If a vendor’s staging environment is breached—even briefly—and those devices were being configured with clinical application profiles, the hospital is on the hook.
Why Canadian data residency matters for device staging
Devices staged or imaged outside Canada—even temporarily—create PHI residency complications. A vendor with US-based staging facilities may be subject to the US CLOUD Act, potentially exposing device images and configuration data to foreign jurisdiction access requests.
The question to ask a potential partner isn’t “are you PHIPA compliant?” Everyone says yes. The question is: “Show me your staging facility’s physical and technical safeguards, and show me your breach-notification SLA.”
The answer—or the inability to provide one—tells you whether you’re dealing with a partner who understands healthcare compliance or a reseller who added a healthcare page to their website.
Capital budget alignment and procurement flexibility
A hospital’s capital committee approves $1.2 million for a clinical mobility refresh in October. The devices need to be deployed before March 31 to avoid capital lapse. The BPS-compliant RFP process takes 8–16 weeks. The OEM’s next Canadian allocation lands in February. The staging, imaging, and deployment window is now measured in days, not weeks.
This isn’t a hypothetical. It’s the arithmetic that procurement managers in Canadian hospitals solve every fiscal year.
The challenge intensifies with additional governance requirements. Ontario Health’s June 2024 Operational Direction requires all Health Information System-related procurements to be pre-approved within 30 days of request before contracts can be signed. That’s another step in the timeline—another compression of the window between approval and deployment.
Hospital spending represents approximately 26% of total Canadian health expenditure, growing at 4% annually. The capital dollars are there. The challenge is executing procurement within the constraints the system imposes.
CapEx vs. OpEx—when Device as a Service makes sense
Device as a Service converts unpredictable device CapEx into predictable monthly OpEx with staging, MDM, and service bundled. The model shifts inventory carrying cost to the vendor’s balance sheet and can decouple device deployment from capital-cycle constraints.
For a hospital facing capital lapse risk, DaaS provides a path to deploy devices in the current fiscal year without waiting for the next capital allocation. For a CFO managing cash flow across multiple capital priorities, it converts a large one-time expense into a manageable operating line item.
The trade-off is total cost over the device lifecycle—DaaS typically costs more over five years than outright purchase. But when the alternative is losing approved capital or delaying a deployment that clinical operations need now, the OpEx premium may be worth paying.
Multi-year price holds and currency exposure
Most healthcare-grade mobile computers are priced in USD at the OEM level. A procurement plan built on January exchange rates can be 8–12% over budget by deployment time if the Canadian dollar moves against you.
A sourcing partner that can offer 24–36 month price holds absorbs the currency risk that would otherwise land on the hospital’s capital plan. This isn’t a nice-to-have—it’s a real differentiator that affects whether the approved budget actually covers the approved scope.
The most common procurement failure mode isn’t a bad device selection. It’s a good device selection that can’t be delivered inside the capital window. A sourcing partner with forward-stocking capability can hold OEM allocation against a hospital’s fiscal calendar and release in deployment waves—carrying inventory on their balance sheet so the hospital doesn’t have to race the clock.
Ask any potential partner directly: “Can you hold allocation against our fiscal calendar, and what does that cost?”
The answer reveals whether you’re talking to someone who understands healthcare procurement timelines or someone who fulfils orders as they come in.
Carrier-agnostic sourcing—why it matters more than most hospitals realise
Canadian carrier healthcare programs are built around virtual care platforms, EMR connectivity, and consumer-grade endpoints. They serve an important purpose. But when a hospital needs 300 Zebra TC52ax-HC units with antimicrobial housings and barcode scanning optics, the carrier’s device catalogue doesn’t have them—because clinical-grade rugged devices aren’t part of the carrier-subsidised line card.
This creates a structural gap that surprises procurement teams who assume their existing carrier relationship will cover clinical mobility needs the same way it covers physician smartphones.
The device portfolio gap
Carrier corporate-liable plans certify and subsidise consumer flagships—iPhone, Galaxy S-series, Pixel. These devices work well for physician communication, administrative workflows, and BYOD programs.
Clinical-grade devices require BYOD-style activation or Wi-Fi-only deployment, creating a procurement and support gap. The carrier relationship doesn’t extend to the devices the clinical floors actually need—which means a separate sourcing relationship, a separate support channel, and a separate vendor management workstream.
Network sunset timelines as a procurement trigger
Legacy network shutdowns create procurement urgency that often catches hospitals off guard. The TELUS HSPA+ network shuts down in Manitoba on March 31, 2026, with nationwide shutdown on March 1, 2027. Clinical device fleets still running on 3G IoT modules—medication dispensing carts, patient tracking systems, legacy handhelds—must be replaced, often ahead of the hospital’s planned capital cycle.
A carrier-agnostic sourcing partner evaluates connectivity requirements per facility, not per carrier contract. A hospital system with sites in rural Ontario and urban Quebec may need different carrier coverage at different locations. A single-carrier corporate-liable agreement locks all sites to one network. An independent sourcing partner can recommend the right connectivity per site and the right device per clinical workflow—without being constrained by what one carrier happens to stock.
That flexibility becomes even more important when you consider the procurement pathways Canadian hospitals are actually authorised to use—which is where GPO compatibility and provincial compliance enter the evaluation.
Canadian GPO compatibility and provincial procurement compliance
In Canadian healthcare, the question isn’t just “can this vendor deliver the right device?” It’s “can this vendor deliver the right device through a procurement pathway our hospital is authorised to use?”
The answer depends on GPO contracts, provincial vendor-of-record lists, and BPS Directive compliance—and most clinical device vendors have never navigated this landscape.
Canada has 14 distinct procurement jurisdictions, each with its own legislation, standards, and purchasing authorities. For a procurement manager at a multi-site health system, this means a vendor qualified in Ontario may not be able to transact in British Columbia or Quebec without separate onboarding. The procurement pathway is as important as the product.
The GPO landscape for clinical mobility
HealthPRO Canada serves over 2,000 healthcare facilities across BC, Alberta, Saskatchewan, Manitoba, Ontario, Nova Scotia, Newfoundland, and the territories. Mohawk Medbuy operates nationally. Kinetic GPO and Plexxus—which serves 20 Ontario hospitals with combined annual budgets exceeding $6 billion—round out the major players.
Here’s the gap most procurement teams encounter: GPO contracts for enterprise mobility are far less mature than contracts for med-surg supplies, pharmaceuticals, or capital medical equipment. The clinical mobility category often doesn’t exist in your GPO’s contract portfolio—or exists only for consumer-grade devices that don’t meet clinical requirements.
When your GPO contract doesn’t include a clinical mobility category, you face a choice: run a standalone BPS-compliant RFP (8–16 weeks minimum) or find a vendor already on a GPO contract that covers the category.
Provincial procurement authorities and the BPS Directive
Ontario’s Broader Public Sector Procurement Directive governs all hospital purchasing above threshold amounts. Supply Ontario centralises provincial procurement. Ontario Health’s pre-approval requirements add another layer for health information system-related purchases.
British Columbia routes through PHSA Supply Chain. Alberta uses AHS CPSM. Quebec mandates the SEAO electronic tendering platform and has distinct language requirements for all vendor documentation.
The practical implication: a vendor needs to understand not just the device, but the procurement pathway in each province where your health system operates. A partner who has already done the GPO onboarding work—HealthPRO, Mohawk Medbuy, or a provincial vendor-of-record—removes months from the procurement timeline.
Ask the question directly: “Are you currently on a GPO contract that our hospital can access?” The answer tells you whether you’re looking at an 8-week deployment or a 6-month procurement process.
Lifecycle visibility and secure decommissioning
Most procurement evaluations focus on getting the device to the nursing unit. Fewer ask what happens when that device reaches end-of-life in four years.
In a PHIPA-regulated environment, the answer matters as much as the initial sourcing decision—because a device that touched patient data requires certified data sanitisation, auditable chain-of-custody documentation, and compliant disposal.
Serialised asset tracking from deployment to decommissioning
A clinical device fleet without serialised asset records is a compliance liability waiting to surface during an audit. The value of tracking isn’t administrative tidiness—it’s knowing exactly which devices are approaching end-of-support before they become security vulnerabilities, which devices haven’t connected to MDM in 90 days, and which devices are sitting in drawers consuming licence fees while providing zero clinical value.
A sourcing partner that provides serialised visibility linked to your CMDB or EMM platform catches these devices before they become audit findings—or breach vectors.
Seventy-three percent of Canadian healthcare organisations experience downtime or technical issues related to their device fleets. Some of that downtime is inevitable hardware failure. But a meaningful portion comes from devices that aged out of support without anyone noticing until something broke.
NIST 800-88 data sanitisation and certificate of destruction
NIST 800-88 is the standard for data erasure in both federal and provincial healthcare contexts. A verbal assurance of “we wipe the devices” is not the same as a per-device certificate of destruction with chain-of-custody documentation.
The most expensive device in a hospital’s fleet isn’t the one that breaks. It’s the one that’s been sitting in a storage closet for 18 months because nobody flagged it as end-of-support. It’s still on the asset register. Still consuming an MDM licence. Still a PHIPA liability if it contains residual clinical data.
The question for any potential partner: “What does your end-of-life documentation look like, and can I see a sample certificate?” If the answer is vague, you’re looking at a reseller, not a lifecycle partner.
What a strong clinical device procurement partnership looks like in practice
After evaluating clinical-grade hardware capability, PHIPA-compliant supply chain handling, capital budget alignment, carrier-agnostic sourcing, GPO compatibility, and lifecycle management, the picture of a strong procurement partner becomes specific.
You’re looking for a single accountable Canadian-domiciled vendor holding MDEL, with clinical-grade OEM authorisations at the highest partner tiers, Canadian staging infrastructure, pre-built PHIPA contractual templates, and the ability to synchronise device delivery with your fiscal calendar.
That’s a short list in the Canadian market.
The questions that separate real partners from resellers
Before your next vendor conversation, here’s a checklist worth bringing:
- What is your Health Canada MDEL number, and can you confirm it’s active? (Verify at Health Canada’s MDEL Listing—the annual fee is $5,060, and active licences are publicly searchable.)
- What is your OEM partner tier with Zebra Technologies, Honeywell, or the manufacturer of the devices we’re specifying? What does that tier mean for Canadian allocation priority?
- Do you have a template PHIPA agent agreement, and what is your breach-notification SLA?
- Where is your staging facility located? Is it in Canada, and can we audit it?
- What is your current inventory position on the specific SKUs we need, and can you hold allocation against our fiscal calendar?
- Are you currently on a GPO contract (HealthPRO, Mohawk Medbuy, or provincial VOR) that our hospital can access?
- What does your end-of-life data sanitisation process look like? Can you provide a sample per-device certificate of destruction?
- If the device model we specified goes end-of-sale before deployment, what’s your process for identifying and validating successor SKUs?
One question that rarely appears on RFP scorecards but should: “What happens when the device model I specified in my capital plan goes end-of-sale before my deployment date?”
The answer reveals whether you’re working with a sourcing partner or a reseller. A reseller says “we’ll let you know.” A partner says “we flagged the EOL notice three months ago, validated the successor SKU with your clinical informatics team, and updated the procurement documentation.”
How PiiComm approaches clinical device procurement for Canadian health systems
The evaluation criteria outlined above narrow the field considerably. In Canada, the number of vendors that hold Premier-tier OEM authorisations for clinical-grade hardware, operate their own Canadian staging facilities, maintain PHIPA-ready agent agreements, and can transact through healthcare GPO pathways is small.
PiiComm is one of those vendors—and the only pure-play managed mobility services provider in Canada with all five capabilities under one roof.
OEM partnerships and clinical device expertise
PiiComm holds Premier partnership with Zebra Technologies—the highest partner tier—along with Honeywell and Samsung partnerships. This isn’t a marketing claim. It determines allocation priority, pricing tier, and technical escalation access for healthcare-grade SKUs like the TC52ax-HC.
When OEM allocation is constrained—which it routinely is for clinical-grade devices in Canada—partner tier determines who gets devices and who waits. A Premier partner has access to inventory that lower-tier resellers cannot touch.
Canadian staging, PHIPA-compliant deployment, and lifecycle support
PiiComm operates its own Canadian staging and deployment facilities. Devices are received, asset-tagged, imaged with the hospital’s Gold Image configuration, enrolled in MDM (SOTI MobiControl, 42Gears, or the hospital’s platform of choice), and shipped to clinical sites—all from Canadian soil.
The 24/7 bilingual (English/French) service desk is staffed in Canada—not routed through an offshore call centre. Spare-in-the-Air provides pre-staged replacement devices shipped same-day for frontline worker continuity—because when a nurse’s scanner fails at 2 AM, the clinical workflow doesn’t wait for a next-business-day RMA.
The AIM (Asset Intelligence Manager) portal provides real-time fleet visibility, and PiiComm’s secure decommissioning produces chain-of-custody documentation per device with certified data erasure records compliant with NIST 800-88.
PiiComm manages 500,000+ devices across thousands of locations—with 15+ years of managed mobility operations behind that number.
Alternatives worth evaluating
In the interest of genuine comparison: CDW Canada offers a broad IT portfolio with a dedicated healthcare team and can bundle mobility with broader IT procurement. Their strength is breadth—if you need clinical devices alongside a larger infrastructure project, CDW can consolidate vendors.
General IT VARs like Compugen and Softchoice serve Canadian healthcare but typically lack the clinical-grade device specialisation and PHIPA-specific staging infrastructure that purpose-built clinical mobility requires.
Carrier healthcare programs—TELUS Health, Bell Healthcare Solutions, Rogers Business—serve virtual care and EMR connectivity well but don’t address purpose-built clinical hardware sourcing. Their device catalogues focus on consumer-grade endpoints.
GPOs like HealthPRO and Mohawk Medbuy provide procurement pathways but rely on vendor partners for fulfillment. The question is which vendor fulfills under the GPO award—and whether that vendor has the clinical device expertise and Canadian staging infrastructure to execute.
PiiComm’s heritage is in rugged, industrial-grade enterprise mobility—Zebra scanners, Honeywell handhelds, rugged tablets, vehicle-mounted computers. Most managed mobility competitors were built for smartphones and enterprise laptops. When a hospital needs 500 TC52ax-HC units staged with Imprivata single sign-on profiles, enrolled in SOTI MobiControl, and deployed across 12 nursing units in three weeks, the partner’s operational DNA matters.
If you’re evaluating procurement partners for a clinical device program, talk to PiiComm’s clinical mobility team about your specific requirements—device selection, PHIPA staging, GPO pathway, and deployment timeline.
FAQ—clinical device procurement for Canadian healthcare
What is a Medical Device Establishment Licence (MDEL) and why does it matter for clinical device procurement?
Health Canada requires importers and distributors of Class I–IV medical devices to hold an MDEL, with an annual fee of $5,060. Active licences are publicly verifiable. This limits which Canadian resellers can legally hold clinical device inventory—ask any potential vendor for their MDEL number and verify it before proceeding.
How do PHIPA requirements affect which vendors a hospital can use for device staging and deployment?
Under PHIPA, vendors that touch devices containing or destined to contain PHI are classified as “agents” of the health information custodian. Administrative monetary penalties up to $500,000 per organisation are now in force. Hospitals should require a written PHIPA agent agreement with breach-notification SLA from any staging vendor.
Can Canadian hospitals procure clinical-grade devices like the Zebra TC52ax-HC through their carrier?
Clinical-grade rugged devices are channel-only products distributed through OEM-authorised partners, not stocked by Canadian carrier retail channels. Carrier healthcare programs focus on virtual care and EMR connectivity—not purpose-built clinical hardware sourcing. A separate sourcing relationship is typically required.
What questions should a hospital ask when evaluating a clinical device procurement partner?
Key differentiating questions: MDEL number (verify it), OEM partner tier, PHIPA agent agreement availability, Canadian staging location, current inventory position on specific SKUs, GPO contract status, breach-notification SLA, and end-of-life data sanitisation process. The answers separate partners from resellers.
How does Device as a Service (DaaS) work for hospital clinical device programs?
DaaS converts unpredictable device CapEx into predictable monthly OpEx with staging, MDM, and service bundled. The model shifts inventory carrying cost to the vendor’s balance sheet and can decouple deployment from capital-cycle constraints—useful when facing capital lapse risk or cash flow constraints.
What is the typical lead time for clinical-grade mobile devices in Canada?
Canadian hospitals routinely report 8–16 week lead times for healthcare-grade rugged mobile computers versus 1–2 weeks for consumer equivalents. This reflects Canada’s smaller OEM allocation and limited MDEL-licensed distributor pool. A partner with forward-stocking capability can mitigate this significantly.
How do healthcare GPOs like HealthPRO and Mohawk Medbuy fit into clinical device procurement?
HealthPRO serves 2,000+ facilities; Mohawk Medbuy is national. GPO contracts for enterprise mobility are less mature than med-surg categories. GPOs provide procurement pathways but rely on vendor partners for clinical device fulfillment—the question is whether your GPO has a clinical mobility category and which vendor fulfills under it.
What data sanitisation standard should a hospital require at device end-of-life?
NIST 800-88 (Guidelines for Media Sanitization) is the standard for data erasure. PHIPA requires auditable proof of destruction for devices that touched PHI. Require a per-device certificate of destruction with chain-of-custody documentation—not a batch certificate. Specify this in the initial procurement agreement.
The device procurement decision you’re actually making
The evaluation framework in this post covers hardware, compliance, capital alignment, carrier independence, GPO pathways, and lifecycle management. That’s a lot of criteria—but they all point toward a single underlying question.
When you select a clinical device procurement partner, you’re not just choosing who supplies your hardware. You’re choosing who operates inside your PHIPA compliance perimeter. Who holds inventory on their balance sheet so your capital doesn’t lapse. Who answers the phone at 2 AM when a scanner fails on the med-surg floor.
Canadian healthcare workers already lose an average of 3.9 hours per week to technical and device issues—up from 3.4 hours in 2023, with over one-quarter losing more than five hours weekly. Every week a deployment is delayed, every device that fails without a same-day replacement, every end-of-life unit sitting in a drawer still consuming an MDM licence—that’s time taken from patient care.
The devices themselves are well-understood. The clinical informatics teams know what works. The harder question is finding a partner who can actually deliver those devices through Canadian procurement pathways, stage them in Canadian facilities with PHIPA-compliant processes, and support them through a full lifecycle.
That’s the evaluation worth getting right.